Last reviewed · How we verify
Spiramycin 3 (Spiramycin III)
Spiramycin 3 (generic name: Spiramycin III) is a Spiramycin III drug. It is currently in unknown development.
Spiramycin III works by inhibiting protein synthesis in bacteria, preventing them from producing essential proteins and ultimately leading to cell death.
Spiramycin 3 is a small molecule that inhibits the bacterial 70S ribosome. It belongs to the class of inhibitors and is a bacterial 70S ribosome inhibitor.
At a glance
| Generic name | Spiramycin III |
|---|---|
| Drug class | Spiramycin III |
| Therapeutic area | Infectious Disease |
| Phase | unknown |
Mechanism of action
Imagine your body's cells are like factories that produce proteins to keep you healthy. Bacteria are like tiny factories that produce proteins to make them sick. Spiramycin III stops these bacterial factories from working by blocking the production of essential proteins, which ultimately kills the bacteria.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Spiramycin 3 CI brief — competitive landscape report
- Spiramycin 3 updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Spiramycin 3
What is Spiramycin 3?
How does Spiramycin 3 work?
What is the generic name of Spiramycin 3?
What drug class is Spiramycin 3 in?
What development phase is Spiramycin 3 in?
Related
- Drug class: All Spiramycin III drugs
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Infectious Disease
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing